RxDoctor Payments Data

Claire Hiles, MD

Medical Oncology · Las Vegas, NVNPI 1447544473

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $806 of the $918 with a category attached, or 87.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $355 and has fallen 72.1% since, to $99 in 2025.

$918in general payments, 2019–2025

Across 39 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$204
  • E.r. Squibb & Sons, L.L.C.$103
  • Johnson & Johnson$99
  • Ipsen Biopharmaceuticals, Inc$79
  • AbbVie$65
  • Merck$61
  • plus $307 from 13 others

What the payments were for

  • Food & beverage$80688%
  • Education$11212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$187,837
Medicare patients
31
Services billed
5,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide65$1,036,644
TagrissoOsimertinib Mesylate29$469,548
ImbruvicaIbrutinib26$410,363
PomalystPomalidomide17$341,814
BrukinsaZanubrutinib23$332,587
Abiraterone Acetate126$316,475
InlytaAxitinib16$306,467
ErleadaApalutamide20$279,691
SprycelDasatinib12$252,108
XtandiEnzalutamide16$230,994
LonsurfTrifluridine/Tipiracil Hcl25$200,366
EliquisApixaban38$39,353
Imatinib Mesylate37$19,673
XareltoRivaroxaban13$9,581
CreonLipase/Protease/Amylase14$5,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$25$1,036,64465 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$103$593,92329 claims
AstraZenecaTagrisso$18$469,54829 claims
Johnson & JohnsonErleada, Xarelto$99$289,27233 claims
AbbVieCreon$65$5,36014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →